NGM Biopharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
NGM Biopharmaceuticals, Inc.‘s stocks are currently a part of 119 hedge funds’ portfolios, which represents 64.74% of the total amount of its stocks outstanding. This makes up a total of 51.31M shares of NGM Biopharmaceuticals, Inc.. Compared to the previous quarter, the number grew by 8.38% or 3.96M shares more. As for the holding position changes, 41.18% (49) of current hedge fund investors increased the number of shares held, 22.69% (27) of current holders sold a part of the shares held, and 12.61% (15) closed the holdings completely. 21 hedge funds are new holders of NGM Biopharmaceuticals, Inc. stock in Q3 2022, it is 17.65% of total holders.
Hedge funds holding NGM Biopharmaceuticals (Q2 2019 – Q3 2022)
| Q2 2019 | 47 |
|---|---|
| Q3 2019 | 49 |
| Q4 2019 | 58 |
| Q1 2020 | 73 |
| Q2 2020 | 83 |
| Q3 2020 | 81 |
| Q4 2020 | 88 |
| Q1 2021 | 106 |
| Q2 2021 | 105 |
| Q3 2021 | 119 |
| Q4 2021 | 117 |
| Q1 2022 | 110 |
| Q2 2022 | 120 |
| Q3 2022 | 119 |
Hedge funds changes in NGM Biopharmaceuticals positions (Q2 2019 – Q3 2022)
| Q2 2019 | 47 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q3 2019 | 11 | 20 | 9 | 9 | 0 |
| Q4 2019 | 14 | 31 | 7 | 5 | 1 |
| Q1 2020 | 18 | 24 | 17 | 3 | 11 |
| Q2 2020 | 20 | 32 | 18 | 10 | 3 |
| Q3 2020 | 9 | 26 | 30 | 11 | 5 |
| Q4 2020 | 20 | 26 | 30 | 12 | 0 |
| Q1 2021 | 27 | 39 | 18 | 8 | 14 |
| Q2 2021 | 19 | 45 | 20 | 20 | 1 |
| Q3 2021 | 25 | 44 | 25 | 10 | 15 |
| Q4 2021 | 18 | 43 | 32 | 18 | 6 |
| Q1 2022 | 13 | 37 | 39 | 20 | 1 |
| Q2 2022 | 25 | 51 | 25 | 13 | 6 |
| Q3 2022 | 21 | 49 | 27 | 15 | 7 |
Hedge funds changes in NGM Biopharmaceuticals stock options (Q2 2019 – Q3 2022)
| Q2 2019 | 0 | 0 |
|---|---|---|
| Q3 2019 | 0 | 0 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 13,000 | 0 |
| Q3 2020 | 215,000 | 0 |
| Q4 2020 | 651,000 | 0 |
| Q1 2021 | 1,404,000 | 430,000 |
| Q2 2021 | 642,000 | 21,000 |
| Q3 2021 | 7,995,000 | 2,633,000 |
| Q4 2021 | 1,606,000 | 24,000 |
| Q1 2022 | 41,000 | 0 |
| Q2 2022 | 2,078,000 | 0 |
| Q3 2022 | 7,994,000 | 1,350,000 |